Skip to Content
Merck
  • Fibroblast growth factor receptor 4 promotes glioblastoma progression: a central role of integrin-mediated cell invasiveness.

Fibroblast growth factor receptor 4 promotes glioblastoma progression: a central role of integrin-mediated cell invasiveness.

Acta neuropathologica communications (2022-04-29)
Lisa Gabler, Carola Nadine Jaunecker, Sonja Katz, Sushilla van Schoonhoven, Bernhard Englinger, Christine Pirker, Thomas Mohr, Petra Vician, Mirjana Stojanovic, Valentin Woitzuck, Anna Laemmerer, Dominik Kirchhofer, Lisa Mayr, Mery LaFranca, Friedrich Erhart, Sarah Grissenberger, Andrea Wenninger-Weinzierl, Caterina Sturtzel, Barbara Kiesel, Alexandra Lang, Brigitte Marian, Bettina Grasl-Kraupp, Martin Distel, Julia Schüler, Johannes Gojo, Michael Grusch, Sabine Spiegl-Kreinecker, Daniel J Donoghue, Daniela Lötsch, Walter Berger
PMID35484633
ABSTRACT

Glioblastoma (GBM) is characterized by a particularly invasive phenotype, supported by oncogenic signals from the fibroblast growth factor (FGF)/ FGF receptor (FGFR) network. However, a possible role of FGFR4 remained elusive so far. Several transcriptomic glioma datasets were analyzed. An extended panel of primary surgical specimen-derived and immortalized GBM (stem)cell models and original tumor tissues were screened for FGFR4 expression. GBM models engineered for wild-type and dominant-negative FGFR4 overexpression were investigated regarding aggressiveness and xenograft formation. Gene set enrichment analyses of FGFR4-modulated GBM models were compared to patient-derived datasets. Despite widely absent in adult brain, FGFR4 mRNA was distinctly expressed in embryonic neural stem cells and significantly upregulated in glioblastoma. Pronounced FGFR4 overexpression defined a distinct GBM patient subgroup with dismal prognosis. Expression levels of FGFR4 and its specific ligands FGF19/FGF23 correlated both in vitro and in vivo and were progressively upregulated in the vast majority of recurrent tumors. Based on overexpression/blockade experiments in respective GBM models, a central pro-oncogenic function of FGFR4 concerning viability, adhesion, migration, and clonogenicity was identified. Expression of dominant-negative FGFR4 resulted in diminished (subcutaneous) or blocked (orthotopic) GBM xenograft formation in the mouse and reduced invasiveness in zebrafish xenotransplantation models. In vitro and in vivo data consistently revealed distinct FGFR4 and integrin/extracellular matrix interactions. Accordingly, FGFR4 blockade profoundly sensitized FGFR4-overexpressing GBM models towards integrin/focal adhesion kinase inhibitors. Collectively, FGFR4 overexpression contributes to the malignant phenotype of a highly aggressive GBM subgroup and is associated with integrin-related therapeutic vulnerabilities.